Facility handles potent compounds and mAbs

Novasep has become the third contract manufacturer in less than two months to announce potent compound safety certification. The certification, granted by SafeBridge, applies to portions of its Le Mans, France, facility used for the manufacture of highly potent active pharmaceutical ingredients.

In addition to the potent compound certification, Novasep has integrated facilities and expertise for monoclonal antibody production via its acquisition of Belgian CMO Henogen. The company can now claim complete and safe manufacturing solutions for antibody drug conjugates, from early development to commercial scale, according to an announcement.

The certification verifies Novasep's proficiency in the management, evaluation, containment, control and communication elements of HPAI production. It involves a 60-element review of API programs, procedures, containment and control. The certification applies to the R&D laboratories, the kilolab, a manufacturing scale synthesis area and associated quality control laboratories.

As reported earlier, DSM Pharmaceuticals and SAFC also have been recently certified.

- here's the announcement
- see our earlier coverage

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.